Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Semin Oncol

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    June 2024
  1. GIULIA O, Alessandro B, Angelo C, Paolo M, et al
    Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease.
    Semin Oncol. 2024;51.
    PubMed     Abstract available


    September 2023
  2. KIM J, Jeong C, Lee J, Ha J, et al
    Bone-modifying agents for non-small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review.
    Semin Oncol. 2023 Sep 14:S0093-7754(23)00063.
    PubMed     Abstract available


    February 2023
  3. SMITH D, Raices M, Cayol F, Corvatta F, et al
    Is the neutrophil-to-lymphocyte ratio a prognostic factor in non-small cell lung cancer patients who receive adjuvant chemotherapy?
    Semin Oncol. 2023 Feb 6:S0093-7754(23)00007.
    PubMed     Abstract available


    September 2022
  4. BELLUOMINI L, Pilotto S, Avancini A, Insolda J, et al
    Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis.
    Semin Oncol. 2022 Sep 23. pii: S0093-7754(22)00061.
    PubMed     Abstract available


    August 2022
  5. ALBAN J, Kennedy K, Hulbert A, Lighter M, et al
    Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review.
    Semin Oncol. 2022 Aug 28. pii: S0093-7754(22)00052.
    PubMed     Abstract available


  6. KENNEDY K, Hulbert A, Pasquinelli M, Feldman LE, et al
    Impact of CT screening in lung cancer: Scientific evidence and literature review.
    Semin Oncol. 2022 Aug 26. pii: S0093-7754(22)00053.
    PubMed     Abstract available


    July 2022
  7. BERNSTEIN E, Bade BC, Akgun KM, Rose MG, et al
    Barriers and facilitators to lung cancer screening and follow-up.
    Semin Oncol. 2022 Jul 25. pii: S0093-7754(22)00058.
    PubMed     Abstract available


  8. BADE B, Gwin M, Triplette M, Wiener RS, et al
    Comorbidity and life expectancy in shared decision making for lung cancer screening.
    Semin Oncol. 2022 Jul 21. pii: S0093-7754(22)00057.
    PubMed     Abstract available


  9. RAMPARIAG R, Chernyavskiy I, Al-Ajam M, Tsay JJ, et al
    Controversies and challenges in lung cancer screening.
    Semin Oncol. 2022 Jul 20. pii: S0093-7754(22)00056.
    PubMed     Abstract available


  10. GRIER W, Abbas H, Gebeyehu RR, Singh AK, et al
    Military exposures and lung cancer in United States veterans.
    Semin Oncol. 2022 Jul 19. pii: S0093-7754(22)00050.
    PubMed     Abstract available


  11. ALGHANIM F, Li KZ, An M, Verceles AC, et al
    Exploring the effects of racial and socioeconomic factors on timeliness of lung cancer diagnosis and treatment in Baltimore Veterans.
    Semin Oncol. 2022 Jul 19. pii: S0093-7754(22)00055.
    PubMed     Abstract available


  12. KLEIN M, Pragman AA, Wendt C
    Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer.
    Semin Oncol. 2022 Jul 19. pii: S0093-7754(22)00051.
    PubMed     Abstract available


  13. JALAL SI, Guo A, Ahmed S, Kelley MJ, et al
    Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program.
    Semin Oncol. 2022 Jul 19. pii: S0093-7754(22)00054.
    PubMed     Abstract available


  14. HUANG Q, Kemnade J, Cornwell L, Kheradmand F, et al
    Non-small cell lung cancer in the era of immunotherapy.
    Semin Oncol. 2022 Jul 8. pii: S0093-7754(22)00049.
    PubMed     Abstract available


  15. SANKAR K, Zeinali M, Nagrath S, Ramnath N, et al
    Molecular biomarkers and liquid biopsies in lung cancer.
    Semin Oncol. 2022 Jul 3. pii: S0093-7754(22)00047.
    PubMed     Abstract available


  16. BUJARSKI S, Flowers R, Alkhunaizi M, Cuvi D, et al
    Challenges in initiating a lung cancer screening program: Experiences from two VA medical centers.
    Semin Oncol. 2022 Jul 3. pii: S0093-7754(22)00046.
    PubMed     Abstract available


  17. THOMAS T, Patel B, Mitchell J, Whitmer A, et al
    Treating advanced lung cancer in older veterans with comorbid conditions and frailty.
    Semin Oncol. 2022 Jul 3. pii: S0093-7754(22)00044.
    PubMed     Abstract available


  18. HIATT JB, Romine PE, Wu DY
    Improving the efficacy of immunotherapy in small cell lung cancer: Leveraging recent scientific discoveries and tumor-specific antigens.
    Semin Oncol. 2022 Jul 2. pii: S0093-7754(22)00043.
    PubMed     Abstract available


  19. SHIN DS, Park K, Garon E, Dubinett S, et al
    Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer.
    Semin Oncol. 2022 Jul 2. pii: S0093-7754(22)00045.
    PubMed     Abstract available


  20. FAROOQ H, Bien H, Chang V, Becker D, et al
    Loss of function STK11 alterations and poor outcomes in non-small-cell lung cancer: Literature and case series of US Veterans.
    Semin Oncol. 2022 Jul 1. pii: S0093-7754(22)00048.
    PubMed     Abstract available


    June 2022
  21. MAURICE NM, Tanner NT
    Lung cancer screening at the VA: Past, present and future.
    Semin Oncol. 2022 Jun 26. pii: S0093-7754(22)00041.
    PubMed     Abstract available


    April 2022
  22. ABUGHANIMEH O, Kaur A, El Osta B, Ganti AK, et al
    Novel targeted therapies for advanced non-small lung cancer.
    Semin Oncol. 2022 Apr 1. pii: S0093-7754(22)00024.
    PubMed     Abstract available


    February 2022
  23. KEITH RL, Miller YE, Ghosh M, Franklin WA, et al
    Lung cancer: Premalignant biology and medical prevention.
    Semin Oncol. 2022 Feb 27. pii: S0093-7754(22)00013.
    PubMed     Abstract available


    April 2021
  24. LUO Z, Gyawali B, Han S, Shi L, et al
    Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.
    Semin Oncol. 2021;48:141-144.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.